Projects per year
Personal profile
Biography
For more information see: Lupton Group Site
Fundamental science opens door to future applications
Dr David Lupton likens catalysis to a modern-day Philosopher's Stone. Many believed this mythical substance could turn base metals into gold, and David thinks that by converting cheap chemicals into valuable materials for society, catalysis is achieving a modern day equivalent. He hopes that by focusing on fundamental research, such as this transformative process, he can create a foundation for new applications in the future.
Catalysis of chemical reactions involves accelerating the rate of a reaction with an additive that is itself not consumed.
'I'm able to take commodity-cheap chemicals and convert them into valuable chemicals, using something that isn't consumed in the process,' David explains. 'That is an efficient and powerful way of generating valuable materials. My research focuses on the discovery of new catalysts and catalytic reactions that allow us to make the chemicals that can see applications in a range of associated disciplines.'
'If you can make something valuable from something cheap, and not consume the thing that allows that to occur, it's a highly sustainable procedure,' David says.
David says many important scientific discoveries have only been possible through a fundamental understanding of reactivity. But he thinks we still know very little about it.
'My drive for why I do science is about enabling discovery,' David says. 'We discover new catalytic reactivity to allow scientists to access materials that they've never had before. We have some projects that have more obvious application and others that are really just about saying 'I can teach people how to make something that's never been made before'. Then it's for their imagination to run with and see if they can put it in a device.'
Total synthesis is another aspect of David's focus on fundamental science. This involves the complete chemical synthesis of organic molecules from simpler, commercially-available pieces.
'There are lots of interesting medicinal entities in nature,' David admits, but adds the question: 'can we design more efficient ways of manufacturing them in a chemical lab that allow you to use cheaper, more readily available materials?'
David is also collaborating with the CSIRO to develop iridoid-based natural products that could lead to future applications in medicinal chemistry.
'We have technology that allows us to access these types of materials very quickly,' David says. 'We've been able to build families of these molecules that you can't access easily using other techniques. Our technology allows us to get to these families so we can start looking at their biology profiles, to see if there is biological activity.'
But, overall, David believes we're doing ourselves a disservice if we ignore the importance of fundamental science.
'Applied science builds on, amongst other things, new discoveries in chemical reactivity. My perspective is 'we've discovered new reactivity, how can that be used?' The applications can be in a medicinal context. I'm not averse to that, but the legacy that is potentially more interesting to me is perhaps in 50 or 100 years, when a scientist does something that they wouldn't have been able to do without knowledge that we have gained today.'
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Organocatalysis
- Biocatalysis
- Enantioselective
Collaborations and top research areas from the last five years
Projects
- 15 Finished
-
Hydrogen atom transfer via Proton Coupled Electron Transfer
Lupton, D. (Primary Chief Investigator (PCI))
1/11/21 → 9/11/24
Project: Research
-
Multifunctional Platform for Chemical Manufacturing and Energy Materials
Lee, A. (Primary Chief Investigator (PCI)), Bryant, G. (Chief Investigator (CI)), Caruso, R. A. (Chief Investigator (CI)), Chiang, K. (Chief Investigator (CI)), Wilson, K. (Chief Investigator (CI)), Junkers, T. (Chief Investigator (CI)), Polyzos, A. (Chief Investigator (CI)), Qiao, G. (Chief Investigator (CI)), Such, G. K. (Chief Investigator (CI)), Winkler, D. (Chief Investigator (CI)), Chaffee, A. (Chief Investigator (CI)), Tanksale, A. (Chief Investigator (CI)) & Lupton, D. (Chief Investigator (CI))
Australian Research Council (ARC), Monash University – Internal School Contribution, Monash University – Internal Faculty Contribution, Monash University – Internal University Contribution, RMIT University, La Trobe University, University of Melbourne
23/04/21 → 22/04/22
Project: Research
-
Polarity inversion of conjugate acceptors: New opportunities in catalysis
1/01/20 → 31/12/24
Project: Research
-
Luminophores and Photochromes: Towards Molecular Componentry
Lupton, D. (Sponsor) & Ritchie, C. (Primary Chief Investigator (PCI))
Australian Research Council (ARC)
30/01/19 → 10/09/23
Project: Research
-
C=C insertion, C-H bond functionalisation, challenges to organocatalysis.
Australian Research Council (ARC), Monash University
1/01/17 → 31/12/19
Project: Research
-
Asymmetric Ene-Reduction by F420-Dependent Oxidoreductases B (FDOR-B) from Mycobacterium smegmatis
Kang, S. W., Antoney, J., Lupton, D. W., Speight, R., Scott, C. & Jackson, C. J., 17 Apr 2023, In: ChemBioChem. 24, 8, 13 p., e202200797.Research output: Contribution to journal › Article › Research › peer-review
Open Access2 Citations (Scopus) -
Asymmetric Ene-Reduction of α,β-Unsaturated Compounds by F420-Dependent Oxidoreductases A Enzymes from Mycobacterium smegmatis
Kang, S. W., Antoney, J., Frkic, R. L., Lupton, D. W., Speight, R., Scott, C. & Jackson, C. J., 7 Feb 2023, In: Biochemistry. 62, 3, p. 873-891 19 p.Research output: Contribution to journal › Article › Research › peer-review
4 Citations (Scopus) -
Cage hydrocarbons as linkers in dimeric drug design: Case studies with trimethoprim and tedizolid
Vujcic, B., Wyllie, J., Tania, Burns, J., White, K. F., Cromwell, S., Lupton, D. W., Dutton, J. L., Soares da Costa, T. P. & Houston, S. D., 15 Jan 2023, In: Bioorganic and Medicinal Chemistry Letters. 80, 5 p., 129086.Research output: Contribution to journal › Article › Research › peer-review
3 Citations (Scopus) -
Chemoselective Methionine Labelling of Recombinant Trastuzumab Shows High In Vitro and In Vivo Tumour Targeting
Hashad, R., Jap, E., Casey, J. L., Ho, Y. T. C., Wright, A., Thalmann, C., Sleeman, M., Lupton, D. W., Hagemeyer, C. E., Cryle, M. J., Robert, R. & Alt, K., 21 Feb 2023, In: Chemistry - A European Journal. 29, 11, 7 p., e202202491.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
Enantioselective Catalysis by the Umpolung of Conjugate Acceptors Involving N-Heterocyclic Carbene or Organophosphine 1,4-Addition
Nakano, Y., Maddigan-Wyatt, J. T. & Lupton, D. W., 24 Apr 2023, In: Accounts of Chemical Research. 56, 10, p. 1190–1203 14 p.Research output: Contribution to journal › Article › Research › peer-review
19 Citations (Scopus)